Concepedia

Donald Gravenor

DG

Statistics

Publications

10

Citations

548

H-Index

10

Active since

1981

Affiliations

Rutgers Cancer Institute(Current)

Institute for Myeloma & Bone Cancer Research

Rutgers, The State University of New Jersey

Florida Cancer Specialists & Research Institute

Center for Cancer and Blood Disorders

Donald Gravenor is an author at Rutgers Cancer Institute specializing in medicine, oncology, and radiation oncology.

Top concepts

Publications per year

1981–2024

10

Publications

10

Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non–Small-Cell Lung Cancer

Christian Manegold, Donald Gravenor, Donald Woytowitz et al. · Journal of Clinical Oncology · 2008 · 167 citations · Full text

Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial

Ulrich Keilholz, Janice M. Mehnert, Sebastian Bauer et al. · Journal for ImmunoTherapy of Cancer · 2019 · 82 citations · Full text

Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy

James R. Berenson, James Hilger, Ori Yellin et al. · Leukemia · 2014 · 76 citations · Full text

, , +13

Circulating tumor DNA (ctDNA) for informing adjuvant chemotherapy (ACT) in stage II/III colorectal cancer (CRC): Interim analysis of BESPOKE CRC study.

Pashtoon Murtaza Kasi, Vasily N. Aushev, Joe Ensor et al. · Journal of Clinical Oncology · 2024 · 54 citations

, , +23

Phase <scp>I</scp>/<scp>II</scp> trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma

James R. Berenson, Ori Yellin, Alberto Bessudo et al. · British Journal of Haematology · 2012 · 53 citations

Rows per page

1–5 of 10